Acute myeloid leukemia (AML) is characterized by the presence of recurrent chromosomal aberrations. One of these rearrangements, the inv(16), is present in approximately 10% of cases with AML. Patients with this mutation have a relatively good prognosis with a 5-year survival of approximately 50%. By disrupting two genes, the inv(16) results in the formation of a CBFB-MYH11 (core binding factor BFsmooth muscle myosin heavy chain 11) fusion gene. This fusion gene encodes an in-frame CBFB-MYH11 fusion protein that contributes to leukemia development. 1 To date, over 10 different in-frame CBFB-MYH11 fusion transcripts have been described that are caused by variable break points in both CBFB and MYH11. 2 In approximately 90% of CBFB-MYH11-positive cases, the break points cluster downstream in MYH11, whereas in the remaining cases they are located more upstream ( Figure 1 ). By analyzing genomic inv(16) break points, we observed that the MYH11 gene partly overlaps with the NDE1 (nuclear distribution gene E homolog 1) gene. NDE1 and MYH11 are transcribed from opposing DNA strands and at their 3 0 ends the genes overlap at the genomic, transcript as well as coding level (Figure 1) . Interestingly, the frequently occurring downstream break points in MYH11 are located between NDE1 exons 7 and 8. This indicates that these break points disrupt NDE1 coding sequences in addition to MYH11. The break points in NDE1 predict the formation of a truncated protein that lacks the last 19 carboxy terminal amino acids (Figure 1 ). Upstream MYH11 break points do not disrupt NDE1 coding sequences but may disrupt the NDE1 gene in its non-coding part as it is unknown how far NDE1 extends at the 3 0 end (Figure 1 ). These findings indicate that in addition to CBFB and MYH11, NDE1 is disrupted in at least 90% of cases with inv(16)-positive AML.
MYH11 is weakly expressed in normal and inv(16)-negative AML bone marrow samples. In contrast, a significantly higher expression of the relevant MYH11 moiety is observed in all inv(16)-positive cases, due to the fusion to CBFB. Letters to the Editor negative cases (Figure 2 ). Yet a large overlap in NDE1 mRNA expression between inv(16) positive and negative cases was observed, in line with earlier reported expression profiling studies in AML. 4 The lowest NDE1 expression in CBFB-MYH11-positive cases was observed in patients with upstream break points. In these cases, part of the expressed MYH11 moiety (exons 29, 30 and 31) is complementary to part of NDE1 exon 8 expressed sequences (Figure 1 ). Whether this overlap causes destabilization of the NDE1 transcript remains to be seen.
NDE1 codes for a 355 aa protein that physically interacts with LIS1. Inherited LIS1 mutations abrogate NDE1 interactions and cause Miller-Dieker syndrome, which is characterized by a profound neuronal migratory disturbance known as lissencephaly or smooth brain. NDE1 and LIS1 are both required for mitotic progression of cortical progenitors in the developing brain. These proteins regulate neuronal progenitor self-renewal and differentiation during initial phases of cortical development. Loss of NDE1/LIS1 function impairs asymmetric cell division resulting in increased neurogenic division with overproduction of neurons. 5 Recently, a fusion of NDE1 with PDGFRb (plateletderived growth factor receptor-b) was described in a patient with chronic myelomonocytic leukemia. 6 As the break point in NDE1 occurred in intron 5, it did not affect the MYH11 gene. Interestingly, the NDE1-PDGFRb fusion protein was found to be constitutively phosphorylated, possibly as a consequence of homodimerization through the NDE1 moiety. Functional studies showed that NDE1-PDFGRb transformed Ba/F3 cells to interleukin-3-independent growth that could be inhibited by the tyrosine kinase inhibitor imatinib mesylate. 6 Treatment of the NDE1-PDFGRb-positive patient with imatinib resulted in a complete hematological response that was accompanied with disappearance of NDE1-PDGFRb-positive cells as shown by karyotyping and fluorescence in situ hybridization analysis. 7 These data clearly define a role for NDE1 in malignant transformation in CBFB-MYH11-negative leukemia.
Although it has been well established that CBFB-MYH11 contributes to leukemia development, additional mutations are required for complete malignant transformation. At present, it is unclear whether disruption of one NDE1 allele contributes to malignant transformation. If so, this might explain why genomic break points cluster downstream in MYH11, as these also disrupt NDE1. In patients with upstream MYH11 break points, NDE1 is not disrupted and other mutations may be needed to cause full-blown leukemia. It will therefore be interesting to determine whether inv(16) cases with downstream genomic MYH11 break points have a different prognosis compared with those with upstream break points. We conclude that the role of NDE1 in controlling neuronal stem cell division, the contribution of NDE1-PDGFRb to leukemia development and the findings reported here warrant further studies to determine the role of NDE1 in normal and malignant hematopoiesis.
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The authors declare no conflict of interest. In each qPCR, the cDNA input and normalization was as described. 8 Dilution series used for quantification were generated by performing qPCR on serial 10-fold dilutions of cDNA in H 2 O derived from acute promyelocytic leukemia NB4 cells (undiluted set at 100%). For NDE1 qPCR the following primer-probe combination (5 0 -3 0 ) was used: NDE1-for CGCAGACCAAAGCCATTAAAG, NDE1-rev GCTCAAAGTCTTCGAGAGACA-TGA, NDE1-probe (TET) CAGA-GAGCTGGAGCAAGCAAATGACGA. Informed consent for research on rest material from bone marrow punctures and peripheral blood samples was obtained in accordance with the declaration of Helsinki. Consistent with an earlier suggestion of linkage disequilibrium between certain JAK2 haplotypes and polycythemia vera, 1 three independent groups recently reported an association between a specific JAK2 haplotype, designated as 46/1, and JAK2V617F (VF)-or JAK2 exon 12 mutation-positive myeloproliferative neoplasms (MPNs). [2] [3] [4] [5] We confirmed these observations in two recent papers 6,7 and also showed increased JAK2 46/1 haplotype frequency in VF-negative essential thrombocythemia (ET) 6 and primary myelofibrosis (PMF). 7 In the latter two studies, the JAK2 46/1 haplotype frequencies in both PMF (44%) and ET (41%) were significantly higher than that of the Wellcome Trust Case Control Consortium (WTCCC) (24%) or local (28%) control population, but similar in VF-positive versus VF-negative PMF (37 versus 36%) or ET (41 versus 38%), after adjusting for VF allele burden (that is, considering only patients with low allele burden to minimize allelic distortion from acquired uniparental disomy). A functional variant associated with the JAK2 46/1 haplotype could promote altered signaling and influence phenotype in the presence of VF or other JAK-STAT-relevant mutation, such as mutant MPL. Therefore, it is reasonable to consider the possibility that the increased JAK2 46/1 haplotype frequency seen in VF-negative MPN is attributed to the presence of a MPL mutation. The current study tests this hypothesis and also examines JAK2 46/1 haplotype frequency in MPL-mutated MPN.
Study patients were recruited from the Mayo Clinic database of adult PMF and ET patients, after obtaining permission from the institutional review board. Diagnosis was according to the World Health Organization criteria.
8 JAK2V617F and MPL mutation analysis was performed using bone marrow-derived cells, using the previously published methods.
9,10 To screen for the JAK2 46/1 haplotype, we genotyped rs12343867 single nucleotide polymorphism (C/T; the C-allele tags the JAK2 46/1 haplotype), 2 using a commercially available TaqMan SNP genotyping assay (Applied Biosystems Inc, Foster City, CA, USA). JAK2 46/1 haplotype allele frequencies in the study population were compared with those of population (WTCCC; n ¼ 1500) and local (n ¼ 57) controls. 2 For the current study, MPL mutation analysis was performed in 161 consecutive VF-negative patients (median age 55 years; 82 females) with ET (n ¼ 108) or PMF (n ¼ 53). Of these, 12 (B8%) displayed either MPLW515L or MPLW515K, including 6 (6%) of the 108 patients with ET and 6 (B11%) of the 53 patients with PMF. The JAK2 46/1 haplotype (that is, C-allele) frequency among the 149 patients who were negative for both VF and MPL mutation was 38% (CC, 11%; CT, 54%; TT, 35%), which was significantly higher than that seen in both the WTCCC (B24%; Po0.01) and local (28%; P ¼ 0.05) control population. In contrast, the JAK2 46/1 haplotype frequency in MPL-mutated cases (B21%; CC, 0%; CT, 42%; TT, 58%) was similar to both WTCCC (P ¼ 0.7) and local (P ¼ 0.5) controls. The results were similar when we added 10 additional MPL-mutated VF-negative MPN cases from our patient database; considering all the 22 MPL-mutated cases (16 MPLW515L and 6 MPLW515K), C-allele frequency was 25% (CC, 5%; CT, 41%; TT, 54%); P-values for C-allele frequency comparisons with the aforementioned local and population controls were 0.7 and 0.9, respectively.
The observations from the current study support the contention that JAK2 germline genetic variation affects disease susceptibility in BCR-ABL-negative classic MPN in the absence of known JAK-STAT-relevant mutations. However, there may be significant differences in the interaction of haplotype 46/1 with specific disease-relevant mutations, as revealed by our findings in MPL-mutated cases, in which JAK2 46/1 haplotype frequency was similar to those seen in local and population controls. The particular finding suggests that acquisition of a MPL mutation is not influenced by the presence of 46/1, and furthermore, any functional advantage that may result from the 46/1 variant in terms of altered JAK-STAT signaling is irrelevant in the context of MPL mutations. Regardless, a larger study is needed to clarify the relationship between JAK2 46/1 haplotype and MPL-mutated MPN and also to explore the additional impact of other MPN-associated TET2 or ASXL1 mutations.
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